Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis

Hepatology

Volumn 46, Issue 3, 2007, Pages 785-792

  Lazaridis, Konstantinos N ^a,b   Juran, Brian D ^a   Boe, Gwen M ^a   Slusser, Joshua P ^b   De Andrade, Mariza ^b   Homburger, Henry A ^b   Ghosh, Karthik ^b   Dickson, E Rolland ^a   Lindor, Keith D ^a   Petersen, Gloria M ^b  

^a Division of Gastroenterology and Hepatology

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRION ANTIBODY;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DEMOGRAPHY; FAMILY STUDY; FEMALE; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; PEDIGREE; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RACE DIFFERENCE; RELATIVE;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; DISEASE SUSCEPTIBILITY; FAMILY; FEMALE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; MITOCHONDRIA, LIVER;

EID: 34548751132     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21749     Document Type: Article

References (31)

1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353:1261-1273.
2. Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancer 2003;362:53-61.
3. Poupon RE, Lindor KD, Pares A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003;39:12-16.
4. Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128:297-303.
5. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130:715-720.
6. Howel D, Fischbacher CM, Bhopal RS, Gray J, Metcalf JV, James OF. An exploratory population-based case-control study of primary biliary cirrhosis. HEPATOLOGY 2000;31:1055-1060.
7. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. HEPATOLOGY 2005;42:1194-1202.
8. Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. HEPATOLOGY 2003;38:1250-1257.
9. Abdulkarim AS, Petrovic LM, Kim WR, Angulo P, Lloyd RV, Lindor KD. Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol 2004;40:380-384.
10. Xu L, Shen Z, Guo L, Fodera B, Keogh A, Joplin R, et al. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci U S A 2003;100:8454-8459.
11. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 2004;127:485-492.
12. Invernizzi P, Selmi C, Mackay IR, Podda M, Gershwin ME. From bases to basis: linking genetics to causation in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2005;3:401-410.
13. Jones DE, Watt FE, Metcalf JV, Bassendine MF, James OF. Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol 1999;30:402-407.
14. Donaldson P, Agarwal K, Craggs A, Craig W, James O, Jones D. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut 2001;48:397-402.
15. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004;127:1565-1577.
16. Gershwin ME, Rowley M, Davis PA, Leung P, Coppel R, Mackay IR. Molecular biology of the 2-oxo-acid dehydrogenase complexes and anti-mitochondrial antibodies. Prog Liver Dis 1992;10:47-61.
17. Gershwin ME, Ansari AA, Mackay IR, Nakanuma Y, Nishio A, Rowley MJ, et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000;174:210-225.
18. Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet 1996;348:1399-1402.
19. Kisand KE, Metskula K, Kisand KV, Kivik T, Gershwin ME, Uibo R. The follow-up of asymptomatic persons with antibodies to pyruvate dehydrogenase in adult population samples. J Gastroenrerol 2001;36:248-254.
20. Palmer JM, Kirby JA, Jones DE. The immunology of primary biliary cirrhosis: the end of the beginning? Clin Exp Immunol 2002;129:191-197.
21. Feizi T, Naccarato R, Sherlock S, Doniach D. Mitochondrial and other tissue antibodies in relatives of patients with primary biliary cirrhosis. Clin Exp Immunol 1972;10:609-622.
22. Galbraith RM, Smith M, Mackenzie RM, Tee DE, Doniach D, Williams R. High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis. N Engl J Med 1974;290:63-69.
23. Caldwell SH, Leung PS, Spivey JR, Prindiville T, de Medina M, Saicheur T, et al. Antimitochondrial antibodies in kindreds of patients with primary biliary cirrhosis: antimitochondrial antibodies are unique to clinical disease and are absent in asymptomatic family members. HEPATOLOGY 1992;16:899-905.
24. Floreani A, Naccarato R, Chiaramonte M. Prevalence of familial disease in primary biliary cirrhosis in Italy. J Hepatol 1997;26:737-738.
25. Bittencourt PL, Farias AQ, Abrantes-Lemos CP, Goncalves LL, Goncalves PL, Magalhaes EP, et al. Prevalence of immune disturbances and chronic liver disease in family members of patients with primary biliary cirrhosis. J Gastroenterol Hepatol 2004;19:873-878.
26. Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? HEPATOLOGY 1986;6:1279-1284.
27. Irie J, Wu Y, Wicker LS, Rainbow D, Nalesnik MA, Hirsch R, et al. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med 2006;203:1209-1219.
28. Mattalia A, Quaranta S, Leung PS, Bauducci M, Van de Water J, Calvo PL, et al. Characterization of antimitochondrial antibodies in health adults. HEPATOLOGY 1998;27:656-661.
29. Shibata M, Onozuka Y, Morizane T, Koizumi H, Kawaguchi N, Miyakawa H, et al. Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture. J Gastroenterol 2004;39:255-259.
30. Koizumi H, Onozuka Y, Shibata M, Sano K, Ooshima Y, Morizane T, et al. Positive rate of anti-mitochondrial antibody in Japanese corporate workers. [in Japanese] Rinsho Byori 2000;48:966-970.
31. Doniach D, Roitt IM, Walker JG, Sherlock S. Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications. Clin Exp Immunol 1966;1:237-262.